TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22160607

Group type: EXPERIMENTAL
Intervention: Presence of a non-friend
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of a friend in positions allowing easy reach for the object
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speaking with 'I' pronoun
Number of subjects: 0
Study: 21988268

Group type: EXPERIMENTAL
Intervention: Experimental Concentric Group (ECG)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Experimental Eccentric Group (EEG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 21
Study: 18277886

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Omeprazole treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Omeprazole maintenance therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: H. pylori negative status
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Severity of cirrhosis
Number of subjects: 30
Study: 17317931

Group type: EXPERIMENTAL
Intervention: Hybrid exercise protocol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional isometric electrical stimulation program
Number of subjects: 12
Study: 14515063

Group type: EXPERIMENTAL
Intervention: M201V [corrected] CysLT2 receptor variant
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-atopic individuals
Number of subjects: 100
Study: 11193249

Group type: EXPERIMENTAL
Intervention: Continuous alendronate
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cyclical alendronate
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate
Number of subjects: 140

Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 140
Study: 1527228

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 3887847

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atenolol + Hydrochlorothiazide
Number of subjects: 50
Study: 30506183

Group type: EXPERIMENTAL
Intervention: Local injection of botulinum toxin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Physiotherapy of pelvic floor muscles (including functional electrical stimulation and desensitization)
Number of subjects: 58
Study: 29415699

Group type: EXPERIMENTAL
Intervention: Adherence-supporting app with daily treatment reminders and electronic monitor (EM) for Cal/BD cutaneous foam.
Number of subjects: 134

Group type: COMPARATOR
Intervention: Cal/BD cutaneous foam and EM without the app (Control).
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Adherence-supporting app with daily treatment reminders and EM for Cal/BD cutaneous foam.
Number of subjects: 134
Study: 27255755

Group type: EXPERIMENTAL
Intervention: N95 respirators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical masks
Number of subjects: 0
Study: 24884340

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Short-term dynamic therapy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Increased activating affects (AA) within a session
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cognitive therapy and Short-term dynamic therapy
Number of subjects: 47
Study: 22109352

Group type: EXPERIMENTAL
Intervention: Telephone-delivered mixed aerobic and resistance exercise intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 143
Study: 20199819

Group type: EXPERIMENTAL
Intervention: Approach direction from five directions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Working height at six different heights
Number of subjects: 8
Study: 18651155

Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 111

Group type: COMPARATOR
Intervention: PET
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Length-SUV index
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Combined quantitative (length-SUV index) and qualitative (visual) analysis
Number of subjects: 111
Study: 15741033

Group type: EXPERIMENTAL
Intervention: Mandibular angle reduction forceps
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intermaxillary fixation (IMF)
Number of subjects: 46
Study: 11940139

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (80 mJ/pulse, 3 Hz)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dentin Protector (polyurethane‐isocyanate 22.5%; methylenechloride 77.5%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 30
Study: 10803996

Group type: EXPERIMENTAL
Intervention: Preoperative urinary bladder catheterization (with Foley)
Number of subjects: 261

Group type: COMPARATOR
Intervention: No preoperative urinary bladder catheterization (without Foley)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Both groups (with and without Foley)
Number of subjects: 261
Study: 8829879

Group type: EXPERIMENTAL
Intervention: Dobutamine (2, 4, and 6 micrograms min‐1 kg‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium nitroprusside (0.5, 1, and 2 micrograms min‐1 kg‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Comparison of dobutamine and sodium nitroprusside
Number of subjects: 8
Study: 1630677

Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis with SK and rtPA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Standard electrocardiogram
Number of subjects: 56
Study: 6437840

Group type: EXPERIMENTAL
Intervention: DHM 32-550 (high dosage)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: DHM 32-550 (low dosage)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31077081

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 10472
Study: 29183908

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 562

Group type: COMPARATOR
Intervention: Standard treatment arm
Number of subjects: 562
Study: 27428501

Group type: EXPERIMENTAL
Intervention: Individual Shear Rate Therapy (ISRT)
Number of subjects: 14
Study: 25377067

Group type: EXPERIMENTAL
Intervention: Medical treatment to suppress all electrographic seizure activity
Number of subjects: 172

Group type: COMPARATOR
Intervention: No treatment of electroencephalographic status epilepticus
Number of subjects: 172
Study: 22160383

Group type: EXPERIMENTAL
Intervention: Bortezomib-based treatment before and after autologous stem cell transplantation (arm B)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Standard treatment without bortezomib (arm A)
Number of subjects: 354
Study: 20071701

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 903

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Crossover to Ustekinumab after Etanercept
Number of subjects: 903
Study: 18037442

Group type: EXPERIMENTAL
Intervention: Social skills training (16 group training sessions)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine nursing care (control group)
Number of subjects: 66
Study: 16128674

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 1675

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1675
Study: 12138951

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative procedures
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham procedures
Number of subjects: 10
Study: 10431345

Group type: EXPERIMENTAL
Intervention: CHX-GI (3.3% CHX gluconate)
Number of subjects: 19

Group type: COMPARATOR
Intervention: GI cement without CHX
Number of subjects: 19

Group type: COMPARATOR
Intervention: Professional tooth cleaning only
Number of subjects: 19
Study: 7594088

Group type: COMPARATOR
Intervention: Nitroglycerin alone (group I, 14 patients)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nitroglycerin with oral hydralazine (75 mg four times a day, group II, 14 patients)
Number of subjects: 28
Study: 1988576

Group type: EXPERIMENTAL
Intervention: E 50 mg/m2 and prednisolone (LEP)
Number of subjects: 211

Group type: COMPARATOR
Intervention: E 100 mg/m2 and prednisolone (HEP)
Number of subjects: 211
Study: 7051365

Group type: EXPERIMENTAL
Intervention: Guanabenz
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 30
Study: 31876109

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT)
Number of subjects: 5
Study: 30113994

Group type: EXPERIMENTAL
Intervention: Multicomponent circuit training program (EXER)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (CONTROL)
Number of subjects: 54
Study: 28162999

Group type: EXPERIMENTAL
Intervention: ipilimumab 10 mg/kg
Number of subjects: 951

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 951
Study: 26829218

Group type: EXPERIMENTAL
Intervention: Metroplasty with intrauterine palpator (group T)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Metroplasty without intrauterine palpator (group C)
Number of subjects: 90
Study: 24372439

Group type: EXPERIMENTAL
Intervention: Individually tailored oral health educational programme
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard oral health educational programme
Number of subjects: 87
Study: 22916669

Group type: EXPERIMENTAL
Intervention: TMDes
Number of subjects: 152

Group type: COMPARATOR
Intervention: Stabilization splint
Number of subjects: 152

Group type: COMPARATOR
Intervention: Jaw exercise regimen
Number of subjects: 152
Study: 19593733

Group type: EXPERIMENTAL
Intervention: Posterior approach (PA) repair
Number of subjects: 91

Group type: COMPARATOR
Intervention: Anterior approach (AA) repair
Number of subjects: 91
Study: 17453603

Group type: EXPERIMENTAL
Intervention: ADHD probands
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control probands
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Subjects using to get high
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Subjects using alcohol
Number of subjects: 186
Study: 15823119

Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy (TLH)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 78
Study: 11963450

Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study: 9417158

Group type: EXPERIMENTAL
Intervention: Intravenous A1PI (60 mg/kg) infused on days 0, 4, 7, and 14
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 7639298

Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.2 mg/ml twice daily for five days)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Conjunctival autograft
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (balanced saline solution)
Number of subjects: 64
Study: 2231212

Group type: EXPERIMENTAL
Intervention: Maintenance indomethacin therapy (0.2 mg/kg/day for 5 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard indomethacin therapy (three doses) followed by placebo (equivalent volume for 5 days)
Number of subjects: 39
Study: 487757

Group type: EXPERIMENTAL
Intervention: Elective induction of labour at 39-40 weeks
Number of subjects: 228

Group type: COMPARATOR
Intervention: Expectant management until 41 weeks
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Elective induction of labour
Number of subjects: 228

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 228
Study: 31726882

Group type: EXPERIMENTAL
Intervention: Extended-release calcifediol (ERC)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Paricalcitol
Number of subjects: 1000
Study: 31759372

Group type: EXPERIMENTAL
Intervention: Integrated educational program (four 60-min sessions, one session per week)
Number of subjects: 64
Study: 28762081

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 144

Group type: COMPARATOR
Intervention: Previous standard-of-care treatments
Number of subjects: 144
Study: 26200716

Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation (tDCS) over left and right hemisphere
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation over left and right hemisphere
Number of subjects: 0
Study: 23856660

Group type: EXPERIMENTAL
Intervention: Nitrous oxide plus intravenous B-vitamins
Number of subjects: 500

Group type: COMPARATOR
Intervention: Nitrous oxide plus placebo
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: MTHFR C677T or A1298C gene variant
Number of subjects: 500
Study: 22019968

Group type: EXPERIMENTAL
Intervention: Interferential current therapy at 40 Hz
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interferential current therapy at 100 Hz
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interferential current therapy at 180 Hz
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham interferential current therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All active IFC groups (40, 100, 180 Hz)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (active IFC and sham)
Number of subjects: 60
Study: 18443874

Group type: EXPERIMENTAL
Intervention: Transanal endoscopic operation (TEO) using standard endoscopic instruments with 2D visualization.
Number of subjects: 31
Study: 17513706

Group type: EXPERIMENTAL
Intervention: AICAR
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bicycle exercise
Number of subjects: 29
Study: 15638046

Group type: EXPERIMENTAL
Intervention: 169Er-citrate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 44
Study: 11427221

Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 104
Study: 9732339

Group type: EXPERIMENTAL
Intervention: Tight control of blood pressure
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Less tight control of blood pressure
Number of subjects: 1148
Study: 8305323

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream (single application)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream (3 days once-daily therapy)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream (5 days once-daily therapy)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream (7 days once-daily therapy)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream
Number of subjects: 99
Study: 3385111

Group type: EXPERIMENTAL
Intervention: Standard trivalent influenza vaccine (15 micrograms of B/USSR/100/83) + placebo
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Standard trivalent vaccine (15 micrograms of B/USSR/100/83) + supplemental dose (45 micrograms of B/USSR)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Supplemental dose (45 micrograms of B/USSR) + placebo
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 31045894

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1 mg neostigmine/0.5 mg atropine (n = 11)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 2 mg/kg sugammadex (n = 11)
Number of subjects: 34
Study: 28431051

Group type: EXPERIMENTAL
Intervention: First-line endoepicardial VT substrate ablation
Number of subjects: 41
Study: 26132683

Group type: EXPERIMENTAL
Intervention: Correct identification of OCD vignette
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Misidentification of OCD vignette
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Vignette type
Number of subjects: 208
Study: 22773551

Group type: EXPERIMENTAL
Intervention: gemcitabine plus erlotinib
Number of subjects: 281

Group type: COMPARATOR
Intervention: capecitabine plus erlotinib
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: skin rash
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: KRAS wild-type status
Number of subjects: 281
Study: 21492030

Group type: EXPERIMENTAL
Intervention: Tele
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison
Number of subjects: 48
Study: 18725045

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy surgery
Number of subjects: 5
Study: 16473371

Group type: EXPERIMENTAL
Intervention: (123)I‐IPT SPECT in PD patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: (123)I‐IPT SPECT in PSP patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison of V3'' values between PD and PSP
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Comparison of posterior putamen/caudate ratio in PD patients
Number of subjects: 39
Study: 12880604

Group type: EXPERIMENTAL
Intervention: Liquid nutrition supplement
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 10965617

Group type: EXPERIMENTAL
Intervention: Left ventricular assist system with blood drainage from the left ventricle (LV drainage Group)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Left ventricular assist system with blood drainage from the left atrium (LA drainage Group)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 13
Study: 9088996

Group type: EXPERIMENTAL
Intervention: L-asparaginase treatment (10,000 U/m2 every 3-4 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E. coli preparation Asparaginase medac (2500 U/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erwinia preparation Erwinase
Number of subjects: 0
Study: 8178703

Group type: EXPERIMENTAL
Intervention: schema (matrix/map)
Number of subjects: 111

Group type: COMPARATOR
Intervention: nonschema (essay)
Number of subjects: 111
Study: 2947108

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (600 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29540131

Group type: EXPERIMENTAL
Intervention: Adapted National Diabetes Prevention Program (NDPP) with male-only groups and male coaches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Diabetes Prevention Program (DPP)
Number of subjects: 0
Study: 26968644

Group type: EXPERIMENTAL
Intervention: AQX-1125
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 24256139

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Reperfusion
Number of subjects: 69
Study: 22759081

Group type: EXPERIMENTAL
Intervention: Hospital-based home care (HBHC) for 6 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hospital-based care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hospital-based home care (HBHC)
Number of subjects: 60
Study: 20087332

Group type: EXPERIMENTAL
Intervention: Desipramine (DES)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 397
Study: 18751626

Group type: EXPERIMENTAL
Intervention: Antenatal perineal massage (10 minutes daily from 34 weeks of gestation until delivery)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (no perineal massage)
Number of subjects: 234
Study: 16916298

Group type: EXPERIMENTAL
Intervention: Homapak (fixed-dose CQ+S/P combination)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fansidar + CQ
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fansidar (Sulfadoxine alone)
Number of subjects: 32

Group type: COMPARATOR
Intervention: GMP made drugs
Number of subjects: 32
Study: 12562875

Group type: EXPERIMENTAL
Intervention: Fish oil (n-3 polyunsaturated fatty acids, DHA and EPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA (docosahexaenoic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EPA (eicosapentaenoic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA and EPA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lauric acid (saturated fatty acid)
Number of subjects: 0
Study: 10704627

Group type: EXPERIMENTAL
Intervention: Oral estradiol (E2) valerate, 2 mg/day
Number of subjects: 73

Group type: COMPARATOR
Intervention: Transdermal E2 gel, 1 mg/day
Number of subjects: 73
Study: 9356611

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study: 1493959

Group type: EXPERIMENTAL
Intervention: Information sheet and questionnaire provided to clients
Number of subjects: 0
Study: 3933320

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 5778

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5778
Study: 30952510

Group type: EXPERIMENTAL
Intervention: Decision Aid
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual Counseling
Number of subjects: 201
Study: 29297779

Group type: EXPERIMENTAL
Intervention: Partnership and Coping Enhancement Program (PCEP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine care control group
Number of subjects: 100
Study: 26446115

Group type: EXPERIMENTAL
Intervention: Telemedicine pathway
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional in-person care model
Number of subjects: 60
Study: 24259265

Group type: EXPERIMENTAL
Intervention: Capsaicin 8% cutaneous patch
Number of subjects: 1044
Study: 22410103

Group type: EXPERIMENTAL
Intervention: Behavioural support with a standard length reduction programme (34 weeks)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Behavioural support with a short length reduction programme (4 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No support with a standard length reduction programme (34 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No support with a short length reduction programme (4 weeks)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All participants encouraged to use NRT
Number of subjects: 160
Study: 21059257

Group type: EXPERIMENTAL
Intervention: Child-focused intervention approach
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Context-focused intervention approach
Number of subjects: 94

Group type: COMPARATOR
Intervention: Regular care intervention
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ICF-CY domains
Number of subjects: 94
Study: 17927543

Group type: EXPERIMENTAL
Intervention: MMORPG
Number of subjects: 100

Group type: COMPARATOR
Intervention: Arcade, Console, Solo Computer
Number of subjects: 100
Study: 15181577

Group type: EXPERIMENTAL
Intervention: Quadrivalent human/bovine reassortant rotavirus vaccine
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439